May 9 (UPI) — The United States Department of Justice has launched an investigation into Cerebral, a mental health startup that has come under scrutiny for its practices of advertising and prescribing controlled substances, including Xanax and Adderall.
The DOJ is investigating Cerebral for “possible offensesof the Controlled Substances Act, which regulates the distribution of drugs with a high risk of addiction.
The San Francisco-based online company offers prescriptions for some of the conditions for which he offers therapy and counseling services, including attention deficit/hyperactivity disorder, anxiety and insomnia.
In recent months, medical professionals and social media platforms like TikTok and Meta have accused Cerebral of misleading ads linking ADHD to obesity.
Meta and TikTok later removed such ads from its platforms.
After the U.S. Attorney for the Eastern District of New York issued a grand jury subpoena on Wednesday asking for documents, Cerebral stopped issuing controlled substance prescriptions the same day.
The company’s Adderall prescriptions could no longer be filled by certain pharmacies, including CVS and Walmart, beginning in April, and the pharmacy Cerebral described as its preferred choice – Truepill – announced on April 29 that it would only send more Schedule 2 controlled substances like Adderall. to their customers.
“To be clear, at this time, no regulatory or law enforcement authority has charged Cerebral with breaking any law,” Cerebral said. in a report to Insider.
“Cerebral intends to cooperate fully with the investigation, which we have already forwarded to the US Attorney’s office,” read the statement to Insider.